Literature DB >> 16224277

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

Joseph A Blansfield1, Kimberly E Beck, Khoi Tran, James C Yang, Marybeth S Hughes, Udai S Kammula, Richard E Royal, Suzanne L Topalian, Leah R Haworth, Catherine Levy, Steven A Rosenberg, Richard M Sherry.   

Abstract

Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4CD25 T cells. In patients with advanced melanoma, our group reported that administration of anti-CTLA-4 antibody mediated objective cancer regression in 13% of patients. This study also established that the blockade of CTLA-4 was associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and a single case of hypophysitis. Since this initial report, 7 additional patients with anti-CTLA-4 antibody-induced autoimmune hypophysitis have been accumulated. The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16224277      PMCID: PMC2154350          DOI: 10.1097/01.cji.0000178913.41256.06

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  16 in total

1.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.

Authors:  Hironori Ueda; Joanna M M Howson; Laura Esposito; Joanne Heward; Hywel Snook; Giselle Chamberlain; Daniel B Rainbow; Kara M D Hunter; Annabel N Smith; Gianfranco Di Genova; Mathias H Herr; Ingrid Dahlman; Felicity Payne; Deborah Smyth; Christopher Lowe; Rebecca C J Twells; Sarah Howlett; Barry Healy; Sarah Nutland; Helen E Rance; Vin Everett; Luc J Smink; Alex C Lam; Heather J Cordell; Neil M Walker; Cristina Bordin; John Hulme; Costantino Motzo; Francesco Cucca; J Fred Hess; Michael L Metzker; Jane Rogers; Simon Gregory; Amit Allahabadia; Ratnasingam Nithiyananthan; Eva Tuomilehto-Wolf; Jaakko Tuomilehto; Polly Bingley; Kathleen M Gillespie; Dag E Undlien; Kjersti S Rønningen; Cristian Guja; Constantin Ionescu-Tîrgovişte; David A Savage; A Peter Maxwell; Dennis J Carson; Chris C Patterson; Jayne A Franklyn; David G Clayton; Laurence B Peterson; Linda S Wicker; John A Todd; Stephen C L Gough
Journal:  Nature       Date:  2003-04-30       Impact factor: 49.962

2.  Anterior hypophysitis and Hashimoto's disease in a young woman.

Authors:  R B GOUDIE; P H PINKERTON
Journal:  J Pathol Bacteriol       Date:  1962-04

3.  Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

Authors:  Kristin Sanderson; Ronald Scotland; Peter Lee; Dongxin Liu; Susan Groshen; Jolie Snively; Shirley Sian; Geoffrey Nichol; Thomas Davis; Tibor Keler; Michael Yellin; Jeffrey Weber
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

4.  Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy.

Authors:  L Ward; J Paquette; E Seidman; C Huot; F Alvarez; P Crock; E Delvin; O Kämpe; C Deal
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

5.  Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.

Authors:  C A Chambers; T J Sullivan; J P Allison
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

6.  Autoimmune hypophysitis.

Authors:  S Ezzat; R G Josse
Journal:  Trends Endocrinol Metab       Date:  1997-03       Impact factor: 12.015

7.  Lymphocytic hypophysitis: case report.

Authors:  T Abe; K Matsumoto; N Sanno; Y Osamura
Journal:  Neurosurgery       Date:  1995-05       Impact factor: 4.654

8.  Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings.

Authors:  E Thodou; S L Asa; G Kontogeorgos; K Kovacs; E Horvath; S Ezzat
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

9.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

10.  Panhypopituitarism in association with interferon-alpha treatment.

Authors:  W B Chan; C S Cockram
Journal:  Singapore Med J       Date:  2004-02       Impact factor: 1.858

View more
  113 in total

Review 1.  Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.

Authors:  Michael Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 2.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok; James P Allison
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

3.  CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.

Authors:  Peter A Prieto; James C Yang; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Donald E White; Catherine L Levy; Steven A Rosenberg; Giao Q Phan
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

4.  From pharmacology to immunopharmacology.

Authors:  Adam Cohen
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

5.  CTLA4 blockade broadens the peripheral T-cell receptor repertoire.

Authors:  Lidia Robert; Jennifer Tsoi; Xiaoyan Wang; Ryan Emerson; Blanca Homet; Thinle Chodon; Stephen Mok; Rong Rong Huang; Alistair J Cochran; Begoña Comin-Anduix; Richard C Koya; Thomas G Graeber; Harlan Robins; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

6.  Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors:  Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal:  Oncologist       Date:  2019-10-10

Review 7.  Immune-related Adverse Events in Cancer Patients.

Authors:  Daniel J Pallin; Christopher W Baugh; Michael A Postow; Jeffrey M Caterino; Timothy B Erickson; Gary H Lyman
Journal:  Acad Emerg Med       Date:  2018-05-25       Impact factor: 3.451

8.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

Review 9.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  Autoimmune hypophysitis of SJL mice: clinical insights from a new animal model.

Authors:  Shey-Cherng Tzou; Isabella Lupi; Melissa Landek; Angelika Gutenberg; Ywh-Min Tzou; Hiroaki Kimura; Giovanni Pinna; Noel R Rose; Patrizio Caturegli
Journal:  Endocrinology       Date:  2008-04-03       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.